The first-line mCRPC market is highly competitive due to the availability of several efficacious and safe hormonal agents that are well entrenched in this indication. Although these therapies have improved patient outcomes, significant unmet need still remains for novel therapies to build upon these outcomes and provide further benefits to first-line mCRPC patients. In this report, we examine the most important drivers of prescribing behavior and key unmet needs in this indication, and provide an in-depth analysis of the most significant commercial opportunities.

Table of contents

  • Prostate Cancer - Unmet Need - Detailed, Expanded Analysis: First-Line Metastatic Castrate-Resistant Prostate Cancer
    • Treatment Drivers and Goals
      • Overview
      • Physician Rating of Treatment Drivers and Goals in First-Line Metastatic Castrate-Resistant Prostate Cancer
        • Importance of Efficacy Attributes to Prescribing Decisions in First-Line Metastatic Castrate-Resistant Prostate Cancer — United States
        • Importance of Efficacy Attributes to Prescribing Decisions in First-Line Metastatic Castrate-Resistant Prostate Cancer — Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in First-Line Metastatic Castrate-Resistant Prostate Cancer — United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in First-Line Metastatic Castrate-Resistant Prostate Cancer — Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in First-Line Metastatic Castrate-Resistant Prostate Cancer — United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in First-Line Metastatic Castrate-Resistant Prostate Cancer — Europe
      • Stated Versus Derived Importance of Key Treatment Drivers and Goals
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, and Convenience of Administration Attributes to Prescribing Decisions in First-Line Metastatic Castrate-Resistant Prostate Cancer — United States
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, and Convenience of Administration Attributes to Prescribing Decisions in First-Line Metastatic Castrate-Resistant Prostate Cancer — Europe
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
        • Products for First-Line Metastatic Castrate-Resistant Prostate Cancer
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Overall Performance of Key Therapies for First-Line Metastatic Castrate-Resistant Prostate Cancer — United States
        • Overall Performance of Key Therapies for First-Line Metastatic Castrate-Resistant Prostate Cancer — Europe
        • Relative Performance of Key Therapies for First-Line Metastatic Castrate-Resistant Prostate Cancer Across Select Efficacy Attributes — United States
        • Relative Performance of Key Therapies for First-Line Metastatic Castrate-Resistant Prostate Cancer Across Select Efficacy Attributes — Europe
        • Relative Performance of Key Therapies for First-Line Metastatic Castrate-Resistant Prostate Cancer Across Select Safety and Tolerability Attributes — United States
        • Relative Performance of Key Therapies for First-Line Metastatic Castrate-Resistant Prostate Cancer Across Select Safety and Tolerability Attributes — Europe
        • Relative Performance of Key Therapies for First-Line Metastatic Castrate-Resistant Prostate Cancer Across Select Convenience of Administration Attributes — United States
        • Relative Performance of Key Therapies for First-Line Metastatic Castrate-Resistant Prostate Cancer Across Select Convenience of Administration Attributes — Europe
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
        • Surveyed Oncologists' Satisfaction with the Performance of Key Therapies for First-Line Metastatic Castrate-Resistant Prostate Cancer on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors — United States
        • Surveyed Oncologists' Satisfaction with the Performance of Key Therapies for First-Line Metastatic Castrate-Resistant Prostate Cancer on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors — Europe
      • Physician Rating of Unmet Need in First-Line Metastatic Castrate-Resistant Prostate Cancer
        • Surveyed Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in First-Line Metastatic Castrate-Resistant Prostate Cancer — United States
        • Surveyed Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in First-Line Metastatic Castrate-Resistant Prostate Cancer — Europe
        • Surveyed Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in First-Line Metastatic Castrate-Resistant Prostate Cancer — United States
        • Surveyed Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in First-Line Metastatic Castrate-Resistant Prostate Cancer — Europe
        • Surveyed Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in First-Line Metastatic Castrate-Resistant Prostate Cancer — United States
        • Surveyed Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in First-Line Metastatic Castrate-Resistant Prostate Cancer — Europe
      • Unmet Need in First-Line Metastatic Castrate-Resistant Prostate Cancer and Related Indications
        • Surveyed Oncologists' Ascribed Level of Unmet Need in First-Line Metastatic Castrate-Resistant Prostate Cancer and Related Indications — United States
        • Surveyed Oncologists' Ascribed Level of Unmet Need in First-Line Metastatic Castrate-Resistant Prostate Cancer and Related Indications — Europe
    • Opportunity Analysis
      • Areas of Opportunity in the First-Line Metastatic Castrate-Resistant Prostate Cancer Market and Emerging Therapy Insights
        • Opportunity: A Novel Agent That Prolongs Overall Survival
        • Opportunity: A Novel Agent That Delays Disease Progression
        • Opportunity: A Novel Agent That Offers Improved Pain Palliation for Patients with Symptomatic Bone Metastases
        • Opportunity: A Novel Agent That Improves PSA Response Rate
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
        • Attributes and Attribute Levels
        • Assigned Prohibitions for the Conjoint Module
      • Attribute Importance and Part-Worth Utilities
        • First-Line Metastatic Castrate-Resistant Prostate Cancer Target Product Profile Analysis: Attribute Importance
        • First-Line Metastatic Castrate-Resistant Prostate Cancer Target Product Profile Analysis: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • First-Line Metastatic Castrate-Resistant Prostate Cancer Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
        • First-Line Metastatic Castrate-Resistant Prostate Cancer Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
        • First-Line Metastatic Castrate-Resistant Prostate Cancer Market Simulations: Target Product Profiles Included in Scenario 1
        • First-Line Metastatic Castrate-Resistant Prostate Cancer Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
        • First-Line Metastatic Castrate-Resistant Prostate Cancer Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
        • First-Line Metastatic Castrate-Resistant Prostate Cancer Market Simulations: Target Product Profiles Included in Scenario 2

Author(s): Evrim Gurpinar

Evrim Gurpinar, Ph.D., is a Business Insights Analyst in the oncology team at Decision Resources Group.

Prior to joining DRG, Evrim was a Postdoctoral Fellow at the Cancer Research UK Beatson Institute, where he studied the effects of p53 tumor suppressor mutations on cancer cell metabolism. He received his B.S. in Cell and Molecular Biology from Tulane University as a Fulbright Scholar and his Ph.D. from the University of Alabama at Birmingham School of Medicine. His PhD work entailed a preclinical drug development project to identify novel drug candidates for non-small cell lung cancer.


Related Reports

Prostate Cancer - Landscape & Forecast - Disease Landscape & Forecast

Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga (Johnson &a...

View Details

Prostate Cancer - Access & Reimbursement - Detailed, Expanded Analysis (US)

The many premium-priced hormonal therapies for prostate cancer present a financial burden for payers. Moreover, costs are set to increase with the recent approvals of the LHRH antagonist Orgovyx fo...

View Details

Prostate Cancer | Disease Landscape and Forecast | G7 | 2020

Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga (Johnson &a...

View Details

Prostate Cancer - Geographic Focus: China - Prostate Cancer - China In-Depth (China)

Prostate cancer is the most common male urinary tumor and sixth most common male malignant tumor in China. Improved screening tools will result in a significant increase in the diagnosed incidence...

View Details